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Although recent methods for the engineering of antibody–drug conjugates (ADCs) have gone
some way to addressing the challenging issues of ADC construction, signiﬁcant hurdles still
remain. There is clear demand for the construction of novel ADC platforms that offer greater
stability, homogeneity and ﬂexibility. Here we describe a signiﬁcant step towards a platform
for next-generation antibody-based therapeutics by providing constructs that combine
site-speciﬁc modiﬁcation, exceptional versatility and high stability, with retention of antibody
binding and structure post-modiﬁcation. The relevance of the work in a biological context is
also demonstrated in a cytotoxicity assay and a cell internalization study with HER2-positive
and -negative breast cancer cell lines.
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ntibody–drug conjugates (ADCs) are comprised of
antibodies that are armed with highly potent warheads
using various conjugation/linker technologies1–4. This
class of therapeutic combines the directing ability of antibodies
(that is, allowing for discrimination between healthy and diseased
tissue) with the cell-killing ability of potent cytotoxic drugs. This
powerful class of targeted therapy has shown considerable
promise in the treatment of various cancers with two US Food
and Drug Administration (FDA)-approved ADCs currently on
the market (Adcetris and Kadcyla) and over 30 ADCs currently in
the clinic5,6. However, in order for ADCs to deliver their full
potential, sophisticated conjugation technologies to connect the
warhead to the antibody and novel strategies and approaches for
their construction are required7,8. Conjugation to native ADCs is
typically achieved through either multiple lysine modiﬁcation or
by functionalization of thiols generated by reduction of interchain
disulﬁde bonds; neither of which is ideal (Fig. 1)7,8. Lysine
modiﬁcation is suboptimal as it results in batch-to-batch
variability and generates heterogeneous ADCs, which have been
shown to have a narrow therapeutic window relative to
homogeneous ADCs, therefore having major pharmacokinetic
limitations9,10. Cysteine modiﬁcation, following interchain
disulﬁde reduction, results in the permanent loss of structural
disulﬁde bonds, which may reduce the stability of the ADC
in vivo7,8. It also generates heterogeneous mixtures when
targeting typical drug-to-antibody ratios. Other approaches
using cysteine-based site-directed mutagenesis and unnatural
amino acids have also been described10,11, but similarly have
limitations, for example, disulﬁde scrambling post-reduction and
high cost combined with relatively low expression yields,
respectively.
Recently, we have described methods for the insertion of small
molecules into disulﬁde bonds in various proteins, engineered
antibody single-chain variable fragments, a fragment antigen-
binding (Fab) construct to yield site-selectively modiﬁed products
and a full antibody12–19. This has gone some way to addressing
the issues of site-selective antibody modiﬁcation. There is also
relevant work in this area by Godwin and coworkers, which
highlights an alternative set of reagents for site-selective disulﬁde
bridging of antibodies20. However, signiﬁcant barriers still remain
in this rapidly evolving ﬁeld and there is demand for novel ways
of constructing ADCs with stable and versatile linkers with
retention of core antibody structure1–6.
In this manuscript, we describe a signiﬁcant step towards
a platform for next-generation ADCs by providing constructs
that combine site-speciﬁc native antibody modiﬁcation, excep-
tional versatility (via a ‘dual click’ approach), high stability
and retention of antibody structure post-modiﬁcation. The
technology, at its core, is based on the insertion of pyridazine-
diones (PDs) bearing orthogonal ‘clickable’ handles into native
disulﬁde bonds in antibody fragments and full antibodies, with a
view to then carry out two orthogonal transformations to yield
multifunctionalized adducts (Fig. 2). This enables the rapid
assembly of dual-modiﬁed ADCs in a highly convergent manner.
The work described herein could pave the way to novel antibody-
based therapeutics.
Results
Antibody scaffold, drug and ﬂuorophore selection. To evaluate
this chemistry, a suitable antibody system and cytotoxic drug
needed to be selected. Trastuzumab (Herceptin), a monoclonal
immunoglobulin G1 (IgG1) that targets the internalizing HER2
receptor, has been used successfully in the treatment of HER2þ
breast cancer and is the antibody component of a recently FDA-
approved ADC therapy for the same indication, trastuzumab
emtansine (Kadcyla)21,22. Anticancer drug doxorubicin (Dox) has
been used as a cytotoxic model payload previously and has a
relatively distinctive absorbance maximum at 495nm to facilitate
determination of drug-to-antibody ratios by ultraviolet–visible
absorption12. As such, Herceptin and Dox were chosen as the
antibody and cytotoxic platforms, respectively. To analyse the
effectiveness of the ‘dual click’ approach on a full antibody
scaffold, where accurate mass spectrometry analysis is limited, a
second light absorbing moiety that absorbs at a distinct
wavelength to Dox was needed to enable facile analysis by
ultraviolet–visible spectrometry of the loading of each cargo. To
this end, a photostable, water-soluble, cyanine-based ﬂuorophore
with a maximum absorbance at 646nm (sulfo-Cy5) was selected.
Choice of linker. In order to deliver a widely applicable and
versatile approach to antibody modiﬁcation, it was rationalized
that an exceptionally stable linker bearing multiple modalities
that could be introduced via conjugation onto native antibodies
was required. A suitable scaffold was dibromopyridazinedione
(diBrPD) as it has previously been shown to be efﬁcient at
inserting into disulﬁde bonds and the resulting constructs to be
exceptionally stable to hydrolysis, even at high temperatures
(Fig. 3)18. Moreover, their structure is appealing as they are
ideally set up for attaching various modalities via each nitrogen
atom. As we wanted the platform to be versatile and widely
applicable, orthogonal ‘clickable’ handles, one on each nitrogen
atom, onto the PD motif were to be attached. To this end, Astra-
PD 1, an alkyne-strained alkyne-pyridazinedione was synthesized
(Fig. 3, see Supplementary Information for details on the
synthesis).
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Figure 1 | Approaches used for the generation of FDA-approved ADCs.
(a) Lysine modiﬁcation leading to a heterogeneous product mixture,
undeﬁned physical and pharmacokinetic properties, and wide distribution of
drug-to-antibody ratio. (b) Modiﬁcation of reduced disulﬁde bonds leading
to a heterogeneous product mixture, loss of structural disulﬁde bonds and a
suboptimal therapeutic index.
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Figure 2 | Functional disulﬁde re-bridging followed by a dual click
approach. Disulﬁde re-bridging by a pyridazinedione construct yields a
site-selectively modiﬁed antibody with dual modalities.
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PD-construct 1 in hand, the insertion of this molecule into a Fab
fragment of Herceptin; Fab-Her 2, by simple reduction of the
single interchain disulﬁde bond, followed by functional disulﬁde
re-bridging with the PD construct was carried out (Fig. 4), which
afforded exclusive formation of a re-bridged Fab fragment with a
PD molecule inserted into the disulﬁde bond, construct 3,b y
mass spectrometry and SDS–PAGE. No further puriﬁcation was
required and a yield in excess of 95% was obtained
(Supplementary Figs 11 and 12).
Moreover, the two orthogonal reactive handles could be
utilized to introduce distinct functionalities selectively. For
example, construct 3 was reacted with PEG4-N3 followed
by reaction with sulfo-Cy5-N3, by applying strain-promoted
azide–alkyne cycloaddition (SPAAC) and copper(I)-catalysed
azide–alkyne cycloaddition (CuAAC) chemistry, respectively, to
form species 5 (Fig. 4). These reactions were shown to be clean
and high yielding with complete selectivity, as demonstrated by
mass spectrometry and SDS–PAGE (Fig. 4 and Supplementary
Figs 13 and 14).
Furthermore, model diethyl-PD-modiﬁed Fab construct 6
(Fab-Diet) was shown to have: (i) comparable binding activity
by enzyme-linked immunosorbent assay (ELISA) to Fab-Her 2;
(ii) excellent stability in blood plasma mimicking conditions for 7
days; (iii) complete stability after 8 months of storage at 4Ci n
phosphate-buffered saline (PBS); and stability in (iv) low pH (3.1)
and (v) high pH (9.0) conditions at 37C over a protracted period
(the blood plasma mimicking conditions correspond to the
simulated body ﬂuid described by Jalota et al.23 with addition of
human serum albumin (600mM, 40mgml 1) and glutathione
(20mM); Fig. 5 and Supplementary Figs 15–20).
There are plentiful opportunities in multimodal imaging and
theranostics, which can be made available by the dual labelling
technology described by attachment of a ﬂuorophore and a
radiolabel or cytotoxic drug, respectively24,25. Furthermore, this
technology allows for the construction of novel ADC fragment-
based products. In terms of therapeutics, antibody fragments offer
potential advantages over full antibodies (for example, fragments
are smaller and offer greater tissue penetration, and many lack the
antibody Fc region and can therefore be expressed in bacterial
cell lines as there is no requirement for post-translational
glycosylation)3,26–28. However, antibody fragments below the
ca. 60–70kDa size cut-off for glomerular ﬁltration lack the
stability afforded by the antibody Fc region and therefore often
have insufﬁcient lifetime in blood serum required to elicit a
beneﬁcial therapeutic effect without intensive and frequent
therapy28–33. It is envisaged that the technology will allow
antibody fragment therapeutics to be far more accessible by
delivering long lifetime antibody fragment–drug conjugates. This
could be achieved by the attachment of an antibody fragment to:
(i) a suitable toxic drug; and (ii) a blood serum-stabilizing
functionality (for example, PEG, albumin or albumin-binding
functionality) to increase lifetime in vivo, using the dual labelling
technology. Moreover, as the chemistry allows for the controlled
stoichiometric addition of each moiety, it will allow for the
construction of well-characterized products.
The construction of an antibody fragment functionalized with
a life-extension technology and a cytotoxic drug was initiated by
choosing Dox as the drug payload and a 20kDa PEG chain as the
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Figure 3 | Properties of dibromopyridazinediones and structure of
Astra-PD 1. (a) General properties of the pyridazinedione platform.
(b) Chemical structure of Astra-PD 1 with an alkyne and a strained
alkyne handle.
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Figure 4 | Sequential modiﬁcations from native Fab-Her 2 to afford Fab-Astra-PEG4-Cy5 5. Re-bridging of Fab-Her 2 and regioselective dual
modiﬁcation using SPAAC with PEG4-N3 followed by CuAAC with Sulfo-Cy5-N3 to yield Fab-Astra-PEG4-Cy5 5 conjugate as a single product.
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characterized in vivo and it does not signiﬁcantly compromise the
penetration ability of a Fab fragment)34–36. As such, Fab-Astra 3
was treated with Dox-N3 (see Supplementary Information for
details on the synthesis) and PEG20k-N3 in a sequential manner
using SPAAC and CuAAC chemistry, respectively, to afford
construct 7 by liquid chromatography–mass spectrometry
(LC–MS) and SDS–PAGE analysis, without the need for gel-
ﬁltration chromatography (Fig. 6 and Supplementary Figs 21
and 22). The formation of this construct with almost complete
retention of binding activity by ELISA on HER2 and no
unspeciﬁc binding observed on EGFR (HER1; Fig. 6 and
Supplementary Fig. 23) paves the way for the appraisal of the
strategy on delivering antibody fragment-based therapeutics. The
retention in binding afﬁnity post-conjugation to a large construct
is due to the installation of the PD-bridging moiety at a position
that is distal from the binding site, which is another important
feature of the chemistry. Moreover, the construction of a wide
variety of similar lifetime extension/drug modalities should
be facile and allow for rapid evaluation of various combinations
S
O O
N
Fab-Diet 6
N
S
0.4
Fab-Diet 6
Fab-Her 2
0.3
0.2
0.1
0
1
150
HSA-HSA
No HSA-Fab
No GSH-Fab
HSA
Fab-Diet
100
80
60
50
40
30
25
100
0
25,000
20,000
25,000
30,000
35,000
40,000
45,000
47864.00
47822.00
50,000
47822.00
47865.00
55,000
60,000 Mass
27,500
30,000
32,500
35,000
37,500
%
100
0
%
100
0
25,000
27,500
30,000
32,500
35,000
37,500
40,000
42,500
45,000
47,500
50,000
52,500
55,000
57,500
60,000
Mass
%
23456
5
Concentration (nM)
250
123 4
150
100
80
60
50
40
30
25
0.5 0.05
A
b
s
o
r
b
a
n
c
e
40,000
42,500
45,000
47,500
50,000
52,500
55,000
57,500
60,000
Mass
297e7
1.48e8
8.73e7
47826.00
35568.00
Expected: 47,820
Observed: 47,826
Expected: 47,820
Observed: 47,822
Expected: 47,820
Observed: 47,822
47868.00
46478.00 49316.00 36166.00
Figure 5 | Activity and stability data for model construct Fab-Diet 6. (a) Structure of Fab-Diet 6.( b) Binding activity data for native Fab-Her 2 and
Fab-Diet 6 assessed by ELISA. (c) SDS–PAGE gel following incubation of Fab-Diet 6 in blood plasma mimicking conditions for 0, 1, 2, 3, 5 and 7 days (lanes
1–6, respectively). (d) SDS–PAGE gel of Fab-Diet 6, Fab-Diet 6 after 8 months of storage at 4C in PBS, Fab-Diet 6 after 24h at 37C in buffer pH 3.1 and
Fab-Diet 6 after 24h at 37C in buffer pH 9.0 (lanes 1–4, respectively). (e) Deconvoluted MS data of Fab-Diet 6 after 8 months of storage at 4C in PBS.
(f) Deconvoluted MS data of Fab-Diet 6 after 24h at 37C in buffer pH 3.1. (g) Deconvoluted MS data of Fab-Diet 6 after 24h at 37C in buffer pH 9.0.
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also further demonstrates the ﬂexibility of the chemistry platform
to allow for the attachment of large constructs such as a 20-kDa
PEG moiety in a facile manner.
Appraisal of dual click strategy on a full antibody. The use of
Astra-PD 1 was then applied to the bridging of disulﬁde bonds in
the full antibody system of trastuzumab (Herceptin), a clinically
approved IgG1 full antibody comprising four disulﬁde bonds.
Successful application of this method on this scaffold would allow
for the construction of a site-speciﬁcally dual-functionalized full
ADC with retention of core antibody structure.
Initially, Herceptin was modiﬁed with PD-construct 1 by
reduction of the full antibody interchain disulﬁde bonds followed
by functional re-bridging. Through optimization of temperature
and concentration of reagents, a full antibody that was re-bridged
in the correct orientation with a 4:1 ratio of PD-to-antibody by
SDS–PAGE and ultraviolet–visible spectrometry was obtained
(Fig. 7 and Supplementary Figs 24 and 25). This provides the ﬁrst
example of functionally re-bridging the disulﬁde bonds of a full
antibody with almost complete retention of full antibody
structure. Following this, the site-selectively modiﬁed full
antibody was functionalized with a drug (Dox-N3) and a
ﬂuorophore (sulfo-Cy5-N3) using click chemistry. It was
conﬁrmed by ultraviolet–visible spectrometry that each species
was attached with a loading of four, and by SDS–PAGE that there
was retention of full antibody structure (Fig. 7 and
Supplementary Figs 24 and 25). Construct 8 was also stable
under a range of pH conditions and in blood plasma mimicking
conditions (Supplementary Figs 26 and 27). These results provide
proof of concept for the ability to attach multiple modalities in a
controlled manner to a full antibody and a new approach for
native antibody functionalization37. Moreover, retention of
binding by ELISA on HER2, and no unspeciﬁc binding on
EGFR (HER1) or evidence of aggregation over a protracted
period could be observed (Fig. 8 and Supplementary Fig. 23).
Internalization study. The effect of the conjugation chemistry on
the internalizing properties of Herceptin and Fab-Her 2 was
appraised next. For this purpose, Herceptin and Fab-Her 2
were directly conjugated to AlexaFluor488 via a PD-linker
to form Her-PD-AlexaFluor488 and Fab-PD-AlexaFluor488
(Supplementary Figs 28 and 29). These constructs were then used
to treat breast cancer cell lines BT-474 (HER2-positive) and
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Figure 6 | Construction of Fab-Astra-Dox-PEG20k 7, a fragment-based ADC with an additional lifetime extension modality. (a) SDS–PAGE analysis
for bioconjugates Fab-Astra-Dox-PEG20k 7 and Fab-Astra-Dox (lanes 1 and 2, respectively). (b) Structure of bioconjugate Fab-Astra-Dox-PEG20k 7.
(c) Deconvoluted MS data of Fab-Astra-Dox.
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Figure 7 | Construction of Her-Astra-Dox-Cy5 8, a dually modiﬁed ADC with both a cytotoxic drug and a ﬂuorophore. (a) Structure of fully
re-bridged and dually functionalized Herceptin. (b) SDS–PAGE analysis of Her-Astra, Her-Astra-Dox, Her-Astra-Dox-Cy5 8 and Herceptin (lanes 1–4,
respectively).
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formed at 4C, a temperature that allowed binding but not
internalization; Her-PD-AlexaFluor488 and Fab-PD-Alexa-
Fluor488 bound to BT-474 cells (Fig. 9a) but not to MDA-MB-
468 cells (Fig. 9b) indicating the speciﬁcity of these constructs to
HER2. Internalization of the bound antibodies occurred when the
temperature was increased to 37C; incubation under these
conditions for 1h resulted in cytoplasmic localization of the
labelled constructs in BT-474 cells (Fig. 9a), thus indicating that
the chemistry employed does not interfere with the internalizing
properties of Herceptin or Fab-Her 2.
Cytotoxicity assay. Finally, the selectivity and cytotoxicity of
constructs Fab-Astra-Dox-PEG20k 7 and Her-Astra-Dox-Cy5 8 in
in vitro studies, using the same HER2-positive and -negative cell
lines in the microscopy studies (that is, BT-474 and MDA-MB-
468), were evaluated. Initially, the sensitivity of both cell lines
to Dox to assess their suitability in a cytotoxicity assay was
appraised. A comparable reduction in cell viability was observed
for both cell lines at similar concentrations of the toxic payload
(IC50¼39 and 10nM for BT-474 and MDA-MB-468, respec-
tively) (Fig. 10a), thus paving the way for toxicity studies with
Dox conjugates 7 and 8. Notably, BT-474 cell viability was
reduced signiﬁcantly when incubated with the conjugates
(IC50¼2.8 and 2.1mM for conjugates 7 and 8, respectively),
especially when compared with the controls of native Herceptin
and Fab-Her 2 where the reduction in cell survival was minimal
at high concentrations (Fig. 10b). In addition, highlighting the
targeted delivery aspect of the method, no toxicity was observed
in analogous studies with MDA-MB-468 cells incubated with
either conjugate 7 or 8 (Fig. 10c). This is consistent with the
observations by microscopy, that is, Herceptin and Fab-Her
conjugates do not appear to bind to these cells, and hence
Dox could not be internalized and thereby cause a toxic effect.
These results highlight the selectivity of conjugates 7 and 8
over Dox alone, and indicate that the toxic drug in conjugates
7 and 8 is delivered by an HER2-dependent internalization
mechanism.
Not only does this chemistry have the potential to make a
signiﬁcant contribution to the current ADC ﬁeld, it is also ﬂexible
and has far reaching scope. Indeed, from a full antibody construct
modiﬁed with Astra-PD 1, it is wholly feasible that entirely new
branches of strategies for ADC development will ensue. For
example, the attachment of drugs that operate by an orthogonal
mechanism of action, which is a concept that is gathering
increasing momentum38–41.
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Figure 9 | Internalization study of fragment-based and full length antibody-based bioconjugates. (a) BT-474 breast cancer cells were treated at
4C with Her-PD-AlexaFluor488 and Fab-PD-AlexaFluor488 (green); both constructs bound at this temperature and were found inside the cells
once internalization was allowed by incubating at 37C for 1h. (b) No signal from ﬂuorophore-conjugated constructs Her-PD-AlexaFluor488 and
Fab-PD-AlexaFluor488 was detected when allowed to bind to the MDA-MB-468 breast cancer cells.
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In conclusion, by the introduction of PD molecules bearing
orthogonal ‘clickable’ handles into the native disulﬁde bonds of
antibodies, we could demonstrate: (i) the opportunity to
synthesize multifunctionalized Fab fragments, which should be
useful in a variety of applications (for example, imaging and
theranostics); (ii) the potential of the technology to make a novel
Fab-based ADC drug candidate; (iii) a new approach to a
multifunctionalized, homogeneous full antibody to open the door
to next-generation full antibody-based drug conjugate therapeu-
tics; (iv) selective internalization into HER2-positive cells with
conjugates of Herceptin and Fab-Her 2 that were directly
conjugated to AlexaFluor488 via a PD-linker; and (v) selective
cell killing over Dox alone for conjugates 7 and 8 on appropriate
HER2 cell lines. Moreover, the ‘plug-and-play’ approach has
broader applications in ﬁelds outside the scope of ADC
technologies (for example, dual warhead antibiotics)39–41.
Methods
General experimental. All reagents were purchased from Sigma-Aldrich,
Promega, Molecular Probes, AlfaAesar, Sino Biological, Invitrogen, UCLH or
Lumiprobe and were used as received. Where described below, petrol refers
to petroleum ether (40–60C). All reactions were monitored by thin-layer
chromatography on pre-coated SIL G/UV254 silica gel plates (254mm) purchased
from VWR. Flash column chromatography was carried out with Kiesegel 60M
0.04/0.063mm (200–400 mesh) silica gel. 1H and 13C NMR spectra were recorded
at ambient temperature on a Bruker Avance 500 instrument operating at a
frequency of 500MHz for 1H and 125MHz for 13C and a Bruker Avance 600
instrument operating at a frequency of 600MHz for 1H and 150MHz for 13Ci n
CDCl3 or CD3OD (as indicated below). The chemical shifts (d)f o r1Ha n d13C are
quoted relative to residual signals of the solvent on the p.p.m. scale. 1H NMR peaks
are reported as singlet (s), doublet (d), triplet (t), quartet (q), quint. (quintet), sext.
(sextet), oct. (octet), m (multiplet), br (broad), dd (doublet of doublet), dt (doublet
of triplets), ABq (AB quartet). Coupling constants (J values) are reported in hertz
(Hz) and are H-H coupling constants unless otherwise stated. Signal multiplicities
in 13C NMR were determined using the distortionless enhancement by phase
transfer spectral editing technique. Infrared spectra were obtained on a Perkin
Elmer Spectrum 100 FTIR Spectrometer operating in ATR mode with frequencies
given in reciprocal centimetres (cm 1). Melting points were measured with a
Gallenkamp apparatus and are uncorrected. Mass spectra of small molecule organic
compounds were obtained on a VG70-SE mass spectrometer.
Protein LC–MS. LC–MS was performed on protein samples using a Waters
Acquity uPLC connected to Waters Acquity Single Quad Detector. Column:
Hypersil Gold C4, 1.9mm, 2.1 50mm; wavelength: 254nm; mobile phase: 95:5
water (0.1% formic acid):MeCN (0.1% formic acid); gradient over 4min (to 5:95
water (0.1% formic acid):MeCN (0.1% formic acid); ﬂow rate: 0.6mlmin 1;M S
mode: ESþ; scan range: m/z¼250–2,000; scan time: 0.25s. Data obtained in
continuum mode. The electrospray source of the MS was operated with a capillary
voltage of 3.5kV and a cone voltage of 50V. Nitrogen was used as the nebulizer
and desolvation gas at a total ﬂow of 600lh 1. Ion series were generated by
integration of the ultraviolet-absorbance (at 254nm) chromatogram over the
1.4–2.0min range. Total mass spectra for protein samples were reconstructed from
the ion series using the MaxEnt 1 algorithm pre-installed on MassLynx software.
Ultraviolet–visible spectroscopy. Ultraviolet–visible spectra were recorded on a
Varian Cary 100 Bio UV-Visible spectrophotometer, operating at room temperature.
Sample buffer was used as blank for baseline correction. Calculation of molecule over
antibody ratio, r, follows the formula below with e280¼215,380M 1cm 1
for Herceptin mAb, e280¼68,590M 1cm 1 for Herceptin Fab, e345¼9,100M 1
cm 1 for Astra-PD, e495¼8,030M 1cm 1 for Dox, e646¼271,000M 1cm 1,
and 0.724, 0.28 and 0.13 as a correction factor (CF) for Dox, Astra-PD and sulfo-
Cy5, respectively, for the absorbance at 280nm.
r ¼
Al=el
ðA280  
P
l CFl   AlÞ
.
e280
With Al the absorbance of a molecule at the wavelength l in nm, and el,t h e
corresponding extinction coefﬁcient.
SDS–PAGE gels. Non-reducing glycine-SDS–PAGE at 12% acrylamide gels were
performed following standard laboratory procedures. A 4% stacking gel was used
and a broad-range molecular weight (MW) marker (10–250kDa, BioLabs) was
co-run to estimate protein weights. Samples (3–5mla tB10mM in total mAb) were
mixed with loading buffer (1–2ml, composition for 6  SDS: 1g SDS, 3ml glycerol,
6ml 0.5M Tris buffer pH 6.8, 2mg R-250 dye) and heated at 75C for 3min.
The gel was run at constant current (30–35mA) for 40min in 1  SDS running
buffer. All gels were stained with Coomassie. Gel photographs were taken with a
Wiko-Stairway device.
Chemical biology. Conjugation of Astra-PD 1 onto Fab-Her 2: To a solution of
Fab-Her 2 (1 eq) in borate buffer (25mM sodium borate, 25mM NaCl, 0.5mM
EDTA, pH 8.0) was added TCEP (3 eq) and the reaction mixture was incubated at
37C for 90min. After this time, was added a solution of Astra-PD 1 in DMF
(5 eq) and the reaction mixture was incubated at 37C for 1h. The excess reagents
were then removed by repeated diaﬁltration into fresh buffer using VivaSpin
sample concentrators (GE Healthcare, 10,000 molecular weight cut-off (MWCO)).
Conjugation of Astra-PD 1 onto Herceptin: To a solution of Herceptin (1 eq) in
borate buffer (25mM sodium borate, 25mM NaCl, 0.5mM EDTA, pH 8.0) was
added TCEP (10 eq) and Astra-PD 1 (20 eq) in DMF and the reaction mixture was
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Figure 10 | Inhibition of cell proliferation in cancer cell lines with
different levels of HER2 expression. (a) BT-474 (HER2-positive) and
MDA-MB-468 (HER2-negative): Dox alone; IC50¼39 and 10nM for
BT-474 and MDA-MB-468, respectively. (b) BT-474: Fab-Astra-Dox-
PEG20k 7, Her-Astra-Dox-Cy5 8 (at similar concentration in Dox) in
comparison with Herceptin and Fab-Her 2;I C 50¼2.8 and 2.1mM for
conjugates 7 and 8, respectively (c) MDA-MB-468: Fab-Astra-Dox-PEG20k
7, Her-Astra-Dox-Cy5 8 (at similar concentration in Dox) in comparison
with Herceptin and Fab-Her 2.
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& 2015 Macmillan Publishers Limited. All rights reserved.incubated at 4C for 6h. The excess reagents were then removed by repeated
diaﬁltration into fresh buffer using VivaSpin sample concentrators (GE Healthcare,
10,000 MWCO).
SPAAC click conditions: To a solution of an antibody or antibody fragment
(1 eq) modiﬁed with Astra-PD 1 in PBS or borate buffer was added azide cargo
(5 eq per re-bridged Astra-PD molecule) and the reaction mixture was incubated at
37C for 4h. The excess reagents were then removed by repeated diaﬁltration into
fresh buffer using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO).
CuAAC click conditions: To a solution of an antibody or antibody fragment
(1 eq) modiﬁed with mono-functionalized-Astra-PD 1 in PBS was added tris(3-
hydroxypropyltriazolylmethyl)amine (1.25mM), CuSO4 (250mM) followed by the
addition of azide cargo (3 eq for Herceptin-Fab-Astra-PD and 10 eq for Herceptin-
Astra-PD) and sodium ascorbate (ﬁnal concentration 5mM), and the reaction
mixture was incubated at 37C for 16h. The excess reagents were then removed by
repeated diaﬁltration into fresh PBS with 2mM EDTA (to remove residual copper
ions) using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO).
Cell lines. Breast cancer cell lines BT-474 and MDA-MB-468 were purchased from
ATCC. BT-474 cells were maintained at 37C, 5% CO2 in Hybricare Medium
(ATCC) complemented with 10% foetal calf serum (Labtech International,
Ringmer, UK). MDA-MB-468 cells were maintained at 37C, 5% CO2 in
Dulbecco’s modiﬁed Eagle’s medium complemented with 10% foetal calf serum
and 2mM L-glutamine (PAA Laboratories, UK).
Internalization analysis by confocal microscopy. Cells on coverslips at
70% conﬂuency were incubated with AlexaFluor488-conjugated constructs at
10mgml 1 for 1h at 4C. Cells were extensively washed with PBS to remove
unbound antibodies and incubated at 37C in growth media. Internalization was
allowed for 1h, followed by extensive washing and ﬁxation with 4% formaldehyde
for 10min at 4C. Coverslips were then blocked with 5% goat serum in 0.3%
Triton-X100 (Sigma). Actin was detected with phalloidin-568 (Invitrogen) and
Hoechst trihydrochloride (Invitrogen) was used to stain cell nuclei. Coverslips were
mounted on slides using ProLong Gold Antifade (Invitrogen) and examined using
Perkin Elmer Spinning Disc Confocal microscope and Volocity Visualization
software.
Toxicity assays. Cells were seeded in 96-well plates at 104 cells/well and allowed to
attach for 24h. Serial dilution of Herceptin, Fab-Her 2, Dox, and conjugates 7 and
8 were added to the cells at concentrations ranging from 40 to 0mM in complete
growth medium. After 96h, cell viability was measured using the CellTiter 96
Aqueous Non-radioactive cell proliferation assay (Promega) following manu-
facturer’s instructions. Cell viability was plotted as percentage of untreated cells.
Ellman’s test. Herceptin and Fab-Her 2, respectively; To a solution of trastuzu-
mab (50ml, 40mM, 1 eq) in phosphate buffer (100mM sodium phosphate, 1mM
EDTA, pH 8.0), was added TCEP (ﬁnal concentration 400mM, 10 eq) and the
reaction mixture was incubated at 37C for 2h. The excess reagents were then
removed by repeated diaﬁltration into fresh buffer using VivaSpin sample con-
centrators (GE Healthcare, 10,000 MWCO). The concentration of protein was then
adjusted to 40mM. Following this, a solution of Ellman’s reagent (5,50-dithio-bis-
(2-nitrobenzoic acid)) in phosphate buffer (100mM sodium phosphate, 1mM
EDTA, pH 8.0; ﬁnal concentration 1.6mM, 40 eq) was added, and the reaction
mixture was incubated at 21C for 30min. Analysis by ultraviolet–visible
spectrometry after a tenfold dilution revealed an absorption at 412nm of 0.439 that
corresponds to 7.8 accessible sulfhydryl groups (e412¼14,150M 1cm 1). A
similar experiment without TCEP reduction before incubation with Ellman’s
reagent showed no absorbance at 412nm.
To a solution of Fab-Her 2 (50ml, 20mM, 1 eq) in phosphate buffer (100mM
sodium phosphate, 1mM EDTA, pH 8.0), was added TCEP (ﬁnal concentration
100mM, 5 eq) and the reaction mixture was incubated at 37C for 2h. The excess
reagents were then removed by repeated diaﬁltration into fresh buffer using
VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The
concentration of protein was then adjusted to 20mM. Following this, a solution of
Ellman’s reagent (5,50-dithio-bis-(2-nitrobenzoic acid)) in phosphate buffer
(100mM sodium phosphate, 1mM EDTA, pH 8.0; ﬁnal concentration 200mM, 10
eq) was added, and the reaction mixture was incubated at 21C for 30min.
Analysis by ultraviolet–visible spectrometry revealed an absorption at 412nm of
0.557 that corresponds to two accessible sulfhydryl groups (e412¼14,150M 1cm 1).
A similar experiment without TCEP reduction before incubation with Ellman’s reagent
showed no absorbance at 412nm.
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